FMFrancesco Marass

Francesco Marass

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesco Marass has a total of 366 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multi-omics of sorafenib responsiveness in HCC patients

    by Eva Dazert, Tujana Boldanova, Charlotte Ky Ng, Marco Colombi, Stefan Wieland, George Rosenberger, Francesco Marass, Salvatore Piscuoglio, Niko Beerenwinkel, Luigi Terracciano, et al.

    Tumor response rates to targeted therapy are generally low. This poses an urgent medical need to identify molecular mechanisms determining responsiveness to inform therapy. We describe the first longitudinal deepscale multi-omic analysis (genomics, transcriptomics, proteomics and phosphoproteomics) of tumor biopsies from eight hepatocellular carcinoma (HCC) patients treated with the targeted kinase inhibitor sorafenib. Three patients were sorafenib responders and five were nonresponders. Resistance did not correlate with a single mutated gene but with genomic instability, especially gain of Chr1q. The patients clustered by therapy response, based on proteomics and phosphoproteomics. Nonresponder tumors showed increased EMT, glycogen storage, splicing and ribosome biogenesis, and decreased carbohydrate and drug metabolism. Resistance also correlated with deregulated phosphorylation of AMPK and NOTCH pathway components. Our data suggest a correlation between dedifferentiation and resistance not evident based on classical clinical staging. We propose potential novel biomarkers to identify and drug combinations to treat sorafenib resistant patients. STATEMENT OF SIGNIFICANCE We provide potential mechanisms of responsiveness to cancer therapy by deep-scale multi-omic analysis of longitudinal tumor biopsies from eight hepatocellular carcinoma (HCC) patients treated with sorafenib.


  • Open Access

    Phylogenetic inference reveals clonal heterogeneity in circulating tumor cell clusters

    by David Gremmelspacher, Johannes Gawron, Barbara M. Szczerba, Katharina Jahn, Francesc Castro-Giner, Jack Kuipers, Jochen Singer, Francesco Marass, Ana Gvozdenovic, Selina Budinjas, et al.

    Circulating tumor cell (CTC) clusters are highly efficient metastatic seeds in various cancers. Yet, their genetic heterogeneity and clonal architecture is poorly characterized. Using whole-exome sequencing coupled with phylogenetic inference from CTC clusters of patients with breast and prostate cancer, as well as mouse cancer models alongside barcode-mediated clonal tracking in vivo, we demonstrate oligoclonal composition of individual CTC clusters. These results improve our understanding of metastasis-relevant clonal dynamics.


  • Open Access

    Data from Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models

    by Richard Mair, Florent Mouliere, Christopher G. Smith, Dineika Chandrananda, Davina Gale, Francesco Marass, Dana W.Y. Tsui, Charles E. Massie, Alan J. Wright, Colin Watts, et al.

    The factors responsible for the low detection rate of cell-free tumor DNA (ctDNA) in the plasma of patients with glioblastoma (GBM) are currently unknown. In this study, we measured circulating nucleic acids in patient-derived orthotopically implanted xenograft (PDOX) models of GBM (n = 64) and show that tumor size and cell proliferation, but not the integrity of the blood–brain barrier or cell death, affect the release of ctDNA in treatment-naïve GBM PDOX. Analysis of fragment length profiles by shallow genome-wide sequencing (<0.2× coverage) of host (rat) and tumor (human) circulating DNA identified a peak at 145 bp in the human DNA fragments, indicating a difference in the origin or processing of the ctDNA. The concentration of ctDNA correlated with cell death only after treatment with temozolomide and radiotherapy. Digital PCR detection of plasma tumor mitochondrial DNA (tmtDNA), an alternative to detection of nuclear ctDNA, improved plasma DNA detection rate (82% vs. 24%) and allowed detection in cerebrospinal fluid and urine. Mitochondrial mutations are prevalent across all cancers and can be detected with high sensitivity, at low cost, and without prior knowledge of tumor mutations via capture-panel sequencing. Coupled with the observation that mitochondrial copy number increases in glioma, these data suggest analyzing tmtDNA as a more sensitive method to detect and monitor tumor burden in cancer, specifically in GBM, where current methods have largely failed.Significance:These findings show that detection of tumor mitochondrial DNA is more sensitive than circulating tumor DNA analysis to detect and monitor tumor burden in patient-derived orthotopic xenografts of glioblastoma.

  • Open Access

    Supplementary Data from Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models

    by Richard Mair, Florent Mouliere, Christopher G. Smith, Dineika Chandrananda, Davina Gale, Francesco Marass, Dana W.Y. Tsui, Charles E. Massie, Alan J. Wright, Colin Watts, et al.

    This file presents demographic information across the different PDOX populations.

  • Open Access

    Data from Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models

    by Richard Mair, Florent Mouliere, Christopher G. Smith, Dineika Chandrananda, Davina Gale, Francesco Marass, Dana W.Y. Tsui, Charles E. Massie, Alan J. Wright, Colin Watts, et al.

    The factors responsible for the low detection rate of cell-free tumor DNA (ctDNA) in the plasma of patients with glioblastoma (GBM) are currently unknown. In this study, we measured circulating nucleic acids in patient-derived orthotopically implanted xenograft (PDOX) models of GBM (n = 64) and show that tumor size and cell proliferation, but not the integrity of the blood–brain barrier or cell death, affect the release of ctDNA in treatment-naïve GBM PDOX. Analysis of fragment length profiles by shallow genome-wide sequencing (<0.2× coverage) of host (rat) and tumor (human) circulating DNA identified a peak at 145 bp in the human DNA fragments, indicating a difference in the origin or processing of the ctDNA. The concentration of ctDNA correlated with cell death only after treatment with temozolomide and radiotherapy. Digital PCR detection of plasma tumor mitochondrial DNA (tmtDNA), an alternative to detection of nuclear ctDNA, improved plasma DNA detection rate (82% vs. 24%) and allowed detection in cerebrospinal fluid and urine. Mitochondrial mutations are prevalent across all cancers and can be detected with high sensitivity, at low cost, and without prior knowledge of tumor mutations via capture-panel sequencing. Coupled with the observation that mitochondrial copy number increases in glioma, these data suggest analyzing tmtDNA as a more sensitive method to detect and monitor tumor burden in cancer, specifically in GBM, where current methods have largely failed.Significance:These findings show that detection of tumor mitochondrial DNA is more sensitive than circulating tumor DNA analysis to detect and monitor tumor burden in patient-derived orthotopic xenografts of glioblastoma.

  • Open Access

    Supplementary Data from Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models

    by Richard Mair, Florent Mouliere, Christopher G. Smith, Dineika Chandrananda, Davina Gale, Francesco Marass, Dana W.Y. Tsui, Charles E. Massie, Alan J. Wright, Colin Watts, et al.

    This file presents demographic information across the different PDOX populations.

  • Open Access

    Supplementary Table 1 from Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models

    by Richard Mair, Florent Mouliere, Christopher G. Smith, Dineika Chandrananda, Davina Gale, Francesco Marass, Dana W.Y. Tsui, Charles E. Massie, Alan J. Wright, Colin Watts, et al.

    This file presents the raw data for the cell free DNA experiments.

  • Open Access

    Supplementary Table 1 from Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models

    by Richard Mair, Florent Mouliere, Christopher G. Smith, Dineika Chandrananda, Davina Gale, Francesco Marass, Dana W.Y. Tsui, Charles E. Massie, Alan J. Wright, Colin Watts, et al.

    This file presents the raw data for the cell free DNA experiments.

  • Top Cited Papers
    Open Access

    Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study

    by Andi Flory, Kristina M. Kruglyak, John A. Tynan, Lisa M. McLennan, Jill M. Rafalko, Patrick Christian Fiaux, Gilberto E. Hernandez, Francesco Marass, Prachi Nakashe, Carlos A. Ruiz-Perez, et al.

    Cancer is the leading cause of death in dogs, yet there are no established screening paradigms for early detection. Liquid biopsy methods that interrogate cancer-derived genomic alterations in cell-free DNA in blood are being adopted for multi-cancer early detection in human medicine and are now available for veterinary use. The CANcer Detection in Dogs (CANDiD) study is an international, multi-center clinical study designed to validate the performance of a novel multi-cancer early detection “liquid biopsy” test developed for noninvasive detection and characterization of cancer in dogs using next-generation sequencing (NGS) of blood-derived DNA; study results are reported here. In total, 1,358 cancer-diagnosed and presumably cancer-free dogs were enrolled in the study, representing the range of breeds, weights, ages, and cancer types seen in routine clinical practice; 1,100 subjects met inclusion criteria for analysis and were used in the validation of the test. Overall, the liquid biopsy test demonstrated a 54.7% (95% CI: 49.3–60.0%) sensitivity and a 98.5% (95% CI: 97.0–99.3%) specificity. For three of the most aggressive canine cancers (lymphoma, hemangiosarcoma, osteosarcoma), the detection rate was 85.4% (95% CI: 78.4–90.9%); and for eight of the most common canine cancers (lymphoma, hemangiosarcoma, osteosarcoma, soft tissue sarcoma, mast cell tumor, mammary gland carcinoma, anal sac adenocarcinoma, malignant melanoma), the detection rate was 61.9% (95% CI: 55.3–68.1%). The test detected cancer signal in patients representing 30 distinct cancer types and provided a Cancer Signal Origin prediction for a subset of patients with hematological malignancies. Furthermore, the test accurately detected cancer signal in four presumably cancer-free subjects before the onset of clinical signs, further supporting the utility of liquid biopsy as an early detection test. Taken together, these findings demonstrate that NGS-based liquid biopsy can offer a novel option for noninvasive multi-cancer detection in dogs.


  • Open Access

    Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients

    by André Franken, Bianca Behrens, Florian Reinhardt, Liwen Yang, Mahdi Rivandi, Francesco Marass, Bernadette Jaeger, Natalia Krawczyk, Jan-Philipp Cieslik, Ellen Honisch, et al.

    Background: The analysis of liquid biopsies, e.g., circulating tumor cells (CTCs) is an appealing diagnostic concept for targeted therapy selection. In this proof-of-concept study, we aimed to perform multiparametric analyses of CTCs to select targeted therapies for metastatic breast cancer patients. Methods: First, CTCs of five metastatic breast cancer patients were analyzed by whole exome sequencing (WES). Based on the results, one patient was selected and monitored by longitudinal and multiparametric liquid biopsy analyses over more than three years, including WES, RNA profiling, and in vitro drug testing of CTCs. Results: Mutations addressable by targeted therapies were detected in all patients, including mutations that were not detected in biopsies of the primary tumor. For the index patient, the clonal evolution of the tumor cells was retraced and resistance mechanisms were identified. The AKT1 E17K mutation was uncovered as the driver of the metastatic process. Drug testing on the patient’s CTCs confirmed the efficacy of drugs targeting the AKT1 pathway. During a targeted therapy chosen based on the CTC characterization and including the mTOR inhibitor everolimus, CTC numbers dropped by 97.3% and the disease remained stable as determined by computer tomography/magnetic resonance imaging. Conclusion: These results illustrate the strength of a multiparametric CTC analysis to choose and validate targeted therapies to optimize cancer treatment in the future. Furthermore, from a scientific point of view, such studies promote the understanding of the biology of CTCs during different treatment regimens.